A new proof-of-concept trial aimed to evaluate the safety of transplanting HCV-infected donor hearts and treating HCV-negative recipients preemptively with DAAs. Preliminary findings were presented at the...
Although approximately 12% of baby boomers are thought to undergo hepatitis C screening, new findings presented at the APHA Annual Meeting & Expo suggest that this estimate may be misleading.
Findings presented at the AASLD’s Liver Meeting shed light on treatment completion and success rates among individuals with hepatitis C virus with ongoing injection drug use and imperfect treatment...
At ACG 2018, hepatologist Mitchell Shiffman, MD, outlined current concerns and special populations in the treatment of hepatitis C virus following the emergence of DAAs.
Using Kaiser Permanente healthcare data, researchers compared the rates of annual kidney function decline and ESKD risk in patients with CKD with and without hepatitis C.
The COVID-19 pandemic disrupted all facets of health care. In a recent study, researchers examined how COVID-19-related health care delays have affected the treatment of hepatitis C virus, and how these...
